Advertisement

Targeting Cancer Metabolism and Cell Cycle by Plant-Derived Compounds

Chapter
First Online:
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1247)

Abstract

Cancer has an increasing death rate over the world population without discriminating between the industrial and developing countries. Complexity of cancer such as ability of cancer cells to develop resistance to drugs or differential behavior of sub-types and different responses from the patients indicate the continuous need for research and development of new anticancer drugs, new formulations of drug combinations and treatment strategies. Not too surprisingly nature itself, is often the largest territorial reservoir as a source for this type of research and development. Speaking of plant variety, more than 1000 plants have already been identified to produce agents with anticancer activities. In this review, a panel of plant derived anti-cancer agents will be reiterated in terms of their mechanism of action in treatment of disease.

Keywords

Cancer Chemotherapy Flavonoids Plants 

Abbreviations

ASPE

Algal sulfated polysaccharide extract

ATP

Adenosine triphosphate

B-myb

Myb-related protein B

CDK4

Cyclin-dependent kinase 4

CDK6

Cyclin-dependent kinase 6

COX-2

Cyclooxygenase-2

CREBP

cAMP-response element-binding protein

CYP1B1

Cytochrome P450 Family 1 Subfamily B Member 1

E2F

Elongation 2 Factor

FASN

Fatty Acid Synthase

FDA

Food and Drug Administration

GLS2

Glutaminase 2

GLUD1/2

Glutamate Dehydrogenase 1/2

HIF1α

Hypoxia-inducible factor 1-alpha

MAPK

Mitogen-activated protein kinase

MCL1

Myeloid cell leukemia 1

mTOR

mammalian target of rapamycin

Myc

Myelocytomatosis

NFKB

Nuclear factor kappa-light-chain-enhancer of activated B

PI3K/AKT

phosphoinositide-3-kinase/Protein kinase B

pRB

protein Retinoblastoma

TCA

Tricarboxylic acid cycle

TNFα

Tumor necrosis factor alpha

VEGF

Vascular endothelial growth factor

WHO

World Health Organization

This is a preview of subscription content, log in to check access.

References

  1. Adekola K, Rosen ST, Shanmugam M (2012) Glucose transporters in cancer metabolism. Curr Opin Oncol 24(6):650–654PubMedPubMedCentralCrossRefGoogle Scholar
  2. Aft RL, Zhang FW, Gius D (2002) Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Brit J Cancer 87(7):805–812PubMedCrossRefGoogle Scholar
  3. Al Dhaheri Y, Eid A, AbuQamar S, Attoub S, Khasawneh M, Aiche G et al (2013) Mitotic arrest and apoptosis in breast cancer cells induced by Origanum majorana extract: upregulation of TNF-alpha and downregulation of survivin and mutant p53. PLoS One 8(2):e56649PubMedPubMedCentralCrossRefGoogle Scholar
  4. Altman BJ, Stine ZE, Dang CV (2016) From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer 16(11):749PubMedCrossRefGoogle Scholar
  5. Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G (2014) Serine and glycine metabolism in cancer. Trends Biochem Sci 39(4):191–198PubMedPubMedCentralCrossRefGoogle Scholar
  6. Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B et al (2003) Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 278(37):35501–35507PubMedCrossRefGoogle Scholar
  7. Bockstaele L, Bisteau X, Paternot S, Roger PP (2009) Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation. Mol Cell Biol 29(15):4188–4200PubMedPubMedCentralCrossRefGoogle Scholar
  8. Bott AJ, Peng IC, Fan YJ, Faubert B, Zhao L, Li JY et al (2015) Oncogenic Myc induces expression of glutamine synthetase through promoter demethylation. Cell Metab 22(6):1068–1077PubMedPubMedCentralCrossRefGoogle Scholar
  9. Brusselmans K, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV (2003) Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer 106(6):856–862PubMedCrossRefGoogle Scholar
  10. Cairns RA, Harris I, McCracken S, Mak TW (2011) Cancer cell metabolism. Cold Spring Harb Symp Quant Biol 76:299–311PubMedCrossRefGoogle Scholar
  11. Chan KS, Koh CG, Li HY (2012) Mitosis-targeted anti-cancer therapies: where they stand. Cell Death Dis 3Google Scholar
  12. Cheong H, Lu C, Lindsten T, Thompson CB (2012) Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol 30(7):671–678PubMedCrossRefGoogle Scholar
  13. Cluntun AA, Lukey MJ, Cerione RA, Locasale JW (2017) Glutamine metabolism in Cancer: understanding the heterogeneity. Trends Cancer 3(3):169–180PubMedPubMedCentralCrossRefGoogle Scholar
  14. Currie E, Schulze A, Zechner R, Walther TC, Farese RV (2013) Cellular fatty acid metabolism and cancer. Cell Metab 18(2):153–161PubMedPubMedCentralCrossRefGoogle Scholar
  15. DeBerardinis RJ, Chandel NS (2016) Fundamentals of cancer metabolism. Sci Adv 2(5):e1600200PubMedPubMedCentralCrossRefGoogle Scholar
  16. Drenzek JG, Seiler NL, Jaskula-Sztul R, Rausch MM, Rose SL (2011) Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines. Gynecol Oncol 122(2):396–401PubMedCrossRefGoogle Scholar
  17. Fischer M, Muller GA (2017) Cell cycle transcription control: DREAM/MuvB and RB-E2F complexes. Crit Rev Biochem Mol Biol 52(6):638–662PubMedCrossRefGoogle Scholar
  18. Flavin R, Peluso S, Nguyen PL, Loda M (2010) Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 6(4):551–562PubMedPubMedCentralCrossRefGoogle Scholar
  19. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T et al (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458(7239):762–765PubMedPubMedCentralCrossRefGoogle Scholar
  20. Hahm ER, Singh KB, Singh SV (2016) c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells. Cell Cycle 15(17):2309–2320PubMedPubMedCentralCrossRefGoogle Scholar
  21. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70CrossRefPubMedGoogle Scholar
  22. Hunt T, Nasmyth K, Novak B (2011) The cell cycle. Philos Trans R Soc Lond Ser B Biol Sci 366(1584):3494–3497CrossRefGoogle Scholar
  23. Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR et al (1996) Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A 93(9):4350–4354PubMedPubMedCentralCrossRefGoogle Scholar
  24. Knudsen ES, Witkiewicz AK (2017) The strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategies. Trends Cancer 3(1):39–55PubMedPubMedCentralCrossRefGoogle Scholar
  25. Kousholt AN, Menzel T, Sorensen CS (2012) Correction: Kousholt, A.N. et al. pathways for genome integrity in G2 phase of the cell cycle. Biomol Ther 2:579–607. Biomolecules. 2013;3(1):72–74Google Scholar
  26. Kuo CY, Ann DK (2018) When fats commit crimes: fatty acid metabolism, cancer stemness and therapeutic resistance. Cancer Commun 38Google Scholar
  27. Lee YJ, Kang YR, Lee SY, Jin Y, Han DC, Kwon BM (2017) Ginkgetin induces G2-phase arrest in HCT116 colon cancer cells through the modulation of bMyb and miRNA34a expression. Int J Oncol 51(4):1331–1342PubMedCrossRefGoogle Scholar
  28. Magalhaes PJ, Carvalho DO, Cruz JM, Guido LF, Barros AA (2009) Fundamentals and health benefits of xanthohumol, a natural product derived from hops and beer. Nat Prod Commun 4(5):591–610PubMedGoogle Scholar
  29. Malumbres M (2014) Cyclin-dependent kinases. Genome Biol 15(6):122PubMedPubMedCentralCrossRefGoogle Scholar
  30. McIntosh JR (2016) Mitosis. Cold Spring Harb Perspect Biol 8(9)Google Scholar
  31. Mills CC, Kolb EA, Sampson VB (2018) Development of chemotherapy with cell-cycle inhibitors for adult and pediatric cancer therapy. Cancer Res 78(2):320–325PubMedPubMedCentralCrossRefGoogle Scholar
  32. Morgan DO (1992) Cell cycle control in normal and neoplastic cells. Curr Opin Genet Dev 2(1):33–37PubMedCrossRefGoogle Scholar
  33. Mukherjee AK, Basu S, Sarkar N, Ghosh AC (2001) Advances in cancer therapy with plant based natural products. Curr Med Chem 8(12):1467–1486PubMedCrossRefGoogle Scholar
  34. Murad H, Hawat M, Ekhtiar A, AlJapawe A, Abbas A, Darwish H et al (2016) Induction of G1-phase cell cycle arrest and apoptosis pathway in MDA-MB-231 human breast cancer cells by sulfated polysaccharide extracted from Laurencia papillosa. Cancer Cell Int 16Google Scholar
  35. Musa J, Aynaud MM, Mirabeau O, Delattre O, Grunewald TG (2017) MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis 8(6):e2895PubMedPubMedCentralCrossRefGoogle Scholar
  36. Nath S, Ghatak D, Das P, Roychoudhury S (2015) Transcriptional control of mitosis: deregulation and cancer. Front Endocrinol (Lausanne) 6:60CrossRefGoogle Scholar
  37. Ooi BK, Chan KG, Goh BH, Yap WH (2018) The role of natural products in targeting cardiovascular diseases via Nrf2 pathway: novel molecular mechanisms and therapeutic approaches. Front Pharmacol 9:1308PubMedPubMedCentralCrossRefGoogle Scholar
  38. Panche AN, Diwan AD, Chandra SR (2016) Flavonoids: an overview. J Nutr Sci 5:e47PubMedPubMedCentralCrossRefGoogle Scholar
  39. Park JB (1999) Flavonoids are potential inhibitors of glucose uptake in U937 cells. Biochem Biophys Res Commun 260(2):568–574PubMedCrossRefGoogle Scholar
  40. Parmar MB, Uludag H (2016) Targeting cyclins and cyclin-dependent kinases involved in cell cycle regulation by RNAi as a potential cancer therapy. Rsc Drug Discov 51:23–45CrossRefGoogle Scholar
  41. Peyressatre M, Prevel C, Pellerano M, Morris MC (2015) Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers (Basel) 7(1):179–237CrossRefGoogle Scholar
  42. Saavedra-Garcia P, Nichols K, Mahmud Z, Fan LYN, Lam EWF (2018) Unravelling the role of fatty acid metabolism in cancer through the FOXO3-FOXM1 axis. Mol Cell Endocrinol 462:82–92PubMedCrossRefGoogle Scholar
  43. Sadasivam S, DeCaprio JA (2013) The DREAM complex: master coordinator of cell cycle-dependent gene expression. Nat Rev Cancer 13(8):585–595PubMedPubMedCentralCrossRefGoogle Scholar
  44. Sala A (2005) B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. Eur J Cancer 41(16):2479–2484PubMedCrossRefGoogle Scholar
  45. Sherr CJ (1995) D-type cyclins. Trends Biochem Sci 20(5):187–190PubMedCrossRefGoogle Scholar
  46. Stevens JF, Page JE (2004) Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry 65(10):1317–1330PubMedCrossRefGoogle Scholar
  47. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108CrossRefGoogle Scholar
  48. Tseng PL, Chen CW, Hu KH, Cheng HC, Lin YH, Tsai WH et al (2018) The decrease of glycolytic enzyme hexokinase 1 accelerates tumor malignancy via deregulating energy metabolism but sensitizes cancer cells to 2-deoxyglucose inhibition. Oncotarget 9(27):18949–18969PubMedPubMedCentralCrossRefGoogle Scholar
  49. Vriens K, Christen S, Parik S, Broekaert D, Yoshinaga K, Talebi A et al (2019) Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature 566(7744):403–406PubMedPubMedCentralCrossRefGoogle Scholar
  50. Wang H, Wu X, Lezmi S, Li Q, Helferich WG, Xu Y et al (2017) Extract of Ginkgo biloba exacerbates liver metastasis in a mouse colon cancer Xenograft model. BMC Complement Altern Med 17(1):516PubMedPubMedCentralCrossRefGoogle Scholar
  51. Weinberg RA (1995) The retinoblastoma protein and cell-cycle control. Cell 81(3):323–330PubMedCrossRefGoogle Scholar
  52. Wise DR, Thompson CB (2010) Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35(8):427–433PubMedPubMedCentralCrossRefGoogle Scholar
  53. Yang XM, Jiang YM, Yang JL, He JR, Sun J, Chen F et al (2015) Prenylated flavonoids, promising nutraceuticals with impressive biological activities. Trends Food Sci Technol 44(1):93–104CrossRefGoogle Scholar
  54. Yao J, Zhang B, Ge C, Peng S, Fang J (2015) Xanthohumol, a polyphenol chalcone present in hops, activating Nrf2 enzymes to confer protection against oxidative damage in PC12 cells. J Agric Food Chem 63(5):1521–1531PubMedCrossRefGoogle Scholar
  55. Yu L, Chen X, Sun XQ, Wang LT, Chen SW (2017) The glycolytic switch in Tumors: how many players are involved? J Cancer 8(17):3430–3440PubMedPubMedCentralCrossRefGoogle Scholar
  56. Zhao XD, Dong N, Man HT, Fu ZL, Zhang MH, Kou S et al (2013) Antiproliferative effect of the Ginkgo biloba extract is associated with the enhancement of cytochrome P450 1B1 expression in estrogen receptor-negative breast cancer cells. Biomed Rep 1(5):797–801PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Bioengineering and GeneticsYeditepe University Faculty of MedicineIstanbulTurkey
  2. 2.Health Institutes of TurkeyTurkish Cancer InstituteIstanbulTurkey

Personalised recommendations

Cite chapter

Buy options